Pacific Biosciences Of California (PACB) Convertible Debt (2021 - 2026)

Pacific Biosciences Of California's Convertible Debt history runs 6 years deep, the most recent figure standing at $644.1 million for Q1 2026.

• On a quarterly basis, Convertible Debt changed 0.33% year-over-year to $644.1 million in Q1 2026; TTM through Mar 2026 was $644.1 million, a 0.33% change from a year earlier, with the FY2025 full-year figure at $645.4 million, changed 0.33% from the prior year.
• Convertible Debt held at $644.1 million in Q1 2026 per PACB's latest filing, from $645.4 million in the prior quarter.
• Across five years, Convertible Debt topped out at $896.8 million in Q1 2023 and bottomed at $644.1 million in Q1 2026.
• The 5-year median for Convertible Debt is $892.2 million (2023), against an average of $806.6 million.
• Across the five-year window, Convertible Debt increased 0.13% in 2024 and fell 27.77% in 2025, its largest moves.
• Year by year, Convertible Debt stood at $896.7 million in 2022, then slipped by 0.5% to $892.2 million in 2023, then slipped by 27.43% to $647.5 million in 2024, then dropped by 0.33% to $645.4 million in 2025, then decreased by 0.2% to $644.1 million in 2026.
• Per Business Quant, the three latest PACB Convertible Debt figures stand at $644.1 million (Q1 2026), $645.4 million (Q4 2025), and $645.2 million (Q3 2025).